Evidence map›Paper›PMID 42086529›Full record

ArticleCell discovery2026

ASB7 promotes osteosarcoma lung metastasis through ubiquitin-mediated degradation of ATF2.

Yezi Zou, Jianliang Zhong, Lanqing Huo, Jiali Chen, Xinhao Yu, Jingxuan Wang, Zhenxuan Chen, Lifeng Yin, Cuiling Zeng, Xia Zhang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yezi Zou *Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Jianliang Zhong *Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Lanqing Huo *Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0002-4578-625X
Jiali Chen *Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Xinhao Yu *Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Jingxuan WangSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Zhenxuan ChenSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.ORCID http://orcid.org/0009-0001-5575-6046
Lifeng YinDepartment of Musculoskeletal Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Cuiling ZengSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Xia ZhangDepartment of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan, China.
Shan HanSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Ruhua ZhangSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China.
Xing-Ding ZhangShenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China. zhangxd39@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-2759-5185
Tiebang KangSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China. kangtb@sysucc.org.cn.ORCID http://orcid.org/0000-0001-8805-4174
Liwen ZhouSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, China. zhoulw@sysucc.org.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273048National Natural Science Foundation of China (National Science Foundation of China) 82341015
6 · The paper itself

Abstract

Osteosarcoma is a highly heterogeneous and aggressive malignancy with a strong propensity for metastasis, highlighting the need to define its molecular drivers. Here, we report that ASB7 promotes tumor cell protrusion formation, invasion, migration, and lung metastasis. High expression of ASB7 is correlated with a poor prognosis. ASB7 forms an E3 ubiquitin ligase complex with CUL5 to ubiquitinate ATF2 at K383 and promote its proteasomal degradation. ATF2 reduction impairs HDAC6 recruitment to the ITGB2 promoter, thereby alleviating the transcriptional repression of ITGB2. Elevated ITGB2 expression subsequently promotes tumor lung metastasis. Our findings reveal that the ASB7-ATF2/HDAC6-ITGB2 axis regulates osteosarcoma metastasis and suggest potential treatment targets.

Identifiers

PMID42086529
PMCPMC13144305

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.